FDA approves Humira biosimilar as first-ever interchangeable monoclonal antibody

Healthcare

Boehringer Ingelheim has shown biosimilar manufacturers the way to win interchangeability with the world’s highest-grossing drug — but the company’s Cyltezo won’t come out until July 2023. Will future Humira competitors have better luck winning an earlier launch date?

Leave a Reply